|
1
|
Shamshiri H, Fatehi F, Abolfazli R,
Harirchian MH, Sedighi B, Zamani B, Roudbari A, Razazian N, Khamseh
F and Nafissi S: Trends of quality of life changes in amyotrophic
lateral sclerosis patients. J Neurol Sci. 368:35–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jenkinson C, Norquist JM and Fitzpatrick
R: Deriving summary indices of health status from the amyotrophic
lateral sclerosis assessment questionnaires (ALSAQ-40 and ALSAQ-5).
J Neurol Neurosurg Psychiatry. 74:242–245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boillée S and Lobsiger CS: Glial cells not
that supportive for motor neurons. Med Sci (Paris). 24:124–126.
2008.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bensimon G, Lacomblez L and Meininger V: A
controlled trial of Riluzole in amyotrophic lateral sclerosis.
ALS/Riluzole Study Group. New J Eng Med. 330:585–591. 1994.
View Article : Google Scholar
|
|
5
|
Traynor BJ, Alexander M, Corr B, Frost E
and Hardiman O: An outcome study of riluzole in amyotrophic lateral
sclerosis - a population-based study in Ireland, 1996–2000. J
Neurol. 250:473–479. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meininger V, Lacomblez L and Salachas F:
What has changed with riluzole? J Neurol. 247:19–22. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rossi S: Australian medicines handbook.
Australian Med Handbook Unit Trust Adelaide. 2013.
|
|
8
|
Ascherio A, Weisskopf MG, O'reilly EJ,
Jacobs EJ, McCullough ML, Calle EE, Cudkowicz M and Thun MJ:
Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann
Neurol. 57:104–110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jones SP, Guillemin GJ and Brew BJ: The
kynurenine pathway in stem cell biology. Int J Tryptophan Res.
6:57–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Geffard M, de Bisschop L, Duleu S,
Hassaine N, Mangas A and Coveñas R: Endotherapia: A new frontier in
the treatment of multiple sclerosis and other chronic diseases.
Discov Med. 10:443–451. 2010.PubMed/NCBI
|
|
11
|
Geffard M, de Bisschop L, Duleu S, Pouns
O, Ferran G, Bessede A, Hassaine N, Autran JL, Bodet D, Mangas A
and Covenas R: Endotherapia. Antiinflamm Antiallergy Agents Med
Chem. 9:197–211. 2010. View Article : Google Scholar
|
|
12
|
Nicaise C, Coupier J, Dabadie MP, De
Decker R, Mangas A, Bodet D, Poncelet L, Geffard M and Pochet R:
Gemals, a new drug candidate, extends lifespan and improves
electromyographic parameters in a rat model of amyotrophic lateral
sclerosis. Amyotroph Lateral Scler. 9:85–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Geffard M, Duleu S, Bessede A, Vigier V,
Bodet D, Mangas A and Coveñas R: GEMSP: A new therapeutic approach
of multiple sclerosis. Cent Nerv Syst Agents Med Chem. 12:173–181.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mangas A, Covenas R, Bodet D, Dabadie MP,
Glaize G and Geffard M: Evaluation of the effects of a new drug on
brain leukocyte infiltration in an experimental model of autoimmune
encephalomyelitis. Lett Drug Des Discov. 3:138–148. 2006.
View Article : Google Scholar
|
|
15
|
Mangas A, Coveñas R, Bodet D, de León M,
Duleu S and Geffard M: Evaluation of the effects of a new drug
candidate (GEMSP) in a chronic EAE model. Int J Biol Sci.
4:150–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mangas A, Coveñas R, Bodet D, Duleu S and
Geffard M: A new drug candidate (GEMSP) for multiple sclerosis.
Curr Med Chem. 16:3203–3214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Couratier P, Marin B, Laurette G, Nicol M
and Preux PM: Epidemiologie, clinical spectrum of ALS and
differential diagnoses. Presse Med. 43:538–548. 2014.(In French).
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kimura F, Fujimura C, Ishida S, Nakajima
H, Furutama D, Uehara H, Shinoda K, Sugino M and Hanafusa T:
Progression rate of ALSFRS-R at time of diagnosis predicts survival
time in ALS. Neurology. 66:265–267. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Labra J, Menon P, Byth K, Morrison S and
Vucic S: Rate of disease progression: A prognostic biomarker in
ALS. J Neurol Neurosurg Psychiatry. 87:628–632. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jenkinson C, Fitzpatrick R, Brennan C,
Bromberg M and Swash M: Development and validation of a short
measure of health status for individuals with amyotrophic lateral
sclerosis/motor neurone disease: The ALSAQ-40. J Neurol. 3 246
Suppl:III16–III21. 1999. View Article : Google Scholar
|
|
21
|
Jenkinson C, Fitzpatrick R, Brennan C and
Swash M: Evidence for the validity and reliability of the ALS
assessment questionnaire: The ALSAQ-40. Amyotroph Lateral Scler
Other Motor Neuron Disord. 1:33–40. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dolfi SC, Medina DJ, Kareddula A, Paratala
B, Rose A, Dhami J, Chen S, Ganesan S, Mackay G, Vazquez A and
Hirshfield KM: Riluzole exerts distinct antitumor effects from a
metabotropic glutamate receptor 1-specific inhibitor on breast
cancer cells. Oncotarget. 8:44639–44653. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
El Idrissi A: Taurine increases
mitochondrial buffering of calcium: Role in neuroprotection. Amino
Acids. 34:321–328. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mangas A, Coveñas R and Geffard M: New
drug therapies for multiple sclerosis. Curr Opin Neurol.
23:287–292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gaydess A, Duysen E, Li Y, Gilman V,
Kabanov A, Lockridge O and Bronich T: Visualization of exogenous
delivery of nanoformulated butyrylcholinesterase to the central
nervous system. Chem Biol Interact. 187:295–298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Zhu H, Li D and Yang X:
Preparation and application of single polyelectrolyte microcapsules
possessing tunable autofluorescent properties. Colloids Surfaces A:
Physicochem Eng Aspects. 329:58–66. 2008. View Article : Google Scholar
|
|
27
|
Blondeau N, Widmann C, Lazdunski M and
Heurteaux C: Polyunsaturated fatty acids induce ischemic and
epileptic tolerance. Neuroscience. 109:231–241. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yoshida H, Yanai H, Namiki Y,
Fukatsu-Sasaki K, Furutani N and Tada N: Neuroprotective effects of
edaravone: A novel free radical scavenger in cerebrovascular
injury. CNS Drug Rev. 12:9–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Crouzin N, de Jesus Ferreira MC,
Cohen-Solal C, Aimar RF, Vignes M and Guiramand J:
Alpha-tocopherol-mediated long-lasting protection against oxidative
damage involves an attenuation of calcium entry through TRP-like
channels in cultured hippocampal neurons. Free Radic Biol Med.
42:1326–1337. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qiu S, Li L, Weeber EJ and May JM:
Ascorbate transport by primary cultured neurons and its role in
neuronal function and protection against excitotoxicity. J Neurosci
Res. 85:1046–1056. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang WP, Iyo AH, Miguel-Hidalgo J,
Regunathan S and Zhu MY: Agmatine protects against cell damage
induced by NMDA and glutamate in cultured hippocampal neurons.
Brain Res. 1084:210–216. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Agar J and Durham H: Relevance of
oxidative injury in the pathogenesis of motor neuron diseases.
Amyotroph Lateral Scler Other Motor Neuron Disord. 4:232–242. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kumari N, Prentice H and Wu JY: Taurine
and its neuroprotective role. Adv Exp Med Biol. 775:19–27. 2013.
View Article : Google Scholar : PubMed/NCBI
|
